With this expansion, the company anticipates to add a 3,000 liter bioreactor train to increase commercial manufacturing in its PF2 site.
The expansion, which is originally started in 2010 with the construction of a multipurpose single-use facility (PF1), expects to include the build-out of a facility to house two 5,000 liter commercial-ready manufacturing lines.
Additionally, the company has also rebranded its corporate image with a new logo and an additional tag line.
CMC Biologics global chief operations officer Gustavo Mahler said the expansion of PF2 will add significant production capacity to CMC Biologics’ existing facilities to accommodate growing demand for cGMP manufacture of biopharmaceuticals.